Your browser doesn't support javascript.
loading
AI-Based Chest CT Analysis for Rapid COVID-19 Diagnosis and Prognosis: A Practical Tool to Flag High-Risk Patients and Lower Healthcare Costs.
Esposito, Giovanni; Ernst, Benoit; Henket, Monique; Winandy, Marie; Chatterjee, Avishek; Van Eyndhoven, Simon; Praet, Jelle; Smeets, Dirk; Meunier, Paul; Louis, Renaud; Kolh, Philippe; Guiot, Julien.
Afiliação
  • Esposito G; Icometrix, 3012 Leuven, Belgium.
  • Ernst B; Pneumology Department, University of Liège, 4000 Liège, Belgium.
  • Henket M; Respiratory Medicine Department, University Hospital of Liège, 4000 Liège, Belgium.
  • Winandy M; Respiratory Medicine Department, University Hospital of Liège, 4000 Liège, Belgium.
  • Chatterjee A; Icometrix, 3012 Leuven, Belgium.
  • Van Eyndhoven S; Icometrix, 3012 Leuven, Belgium.
  • Praet J; Icometrix, 3012 Leuven, Belgium.
  • Smeets D; Icometrix, 3012 Leuven, Belgium.
  • Meunier P; Radiology Department, University Hospital of Liège, 4000 Liège, Belgium.
  • Louis R; Respiratory Medicine Department, University Hospital of Liège, 4000 Liège, Belgium.
  • Kolh P; Information Systems Management Department, University Hospital of Liège, 4000 Liège, Belgium.
  • Guiot J; Respiratory Medicine Department, University Hospital of Liège, 4000 Liège, Belgium.
Diagnostics (Basel) ; 12(7)2022 Jul 01.
Article em En | MEDLINE | ID: mdl-35885513
ABSTRACT
Early diagnosis of COVID-19 is required to provide the best treatment to our patients, to prevent the epidemic from spreading in the community, and to reduce costs associated with the aggravation of the disease. We developed a decision tree model to evaluate the impact of using an artificial intelligence-based chest computed tomography (CT) analysis software (icolung, icometrix) to analyze CT scans for the detection and prognosis of COVID-19 cases. The model compared routine practice where patients receiving a chest CT scan were not screened for COVID-19, with a scenario where icolung was introduced to enable COVID-19 diagnosis. The primary outcome was to evaluate the impact of icolung on the transmission of COVID-19 infection, and the secondary outcome was the in-hospital length of stay. Using EUR 20000 as a willingness-to-pay threshold, icolung is cost-effective in reducing the risk of transmission, with a low prevalence of COVID-19 infections. Concerning the hospitalization cost, icolung is cost-effective at a higher value of COVID-19 prevalence and risk of hospitalization. This model provides a framework for the evaluation of AI-based tools for the early detection of COVID-19 cases. It allows for making decisions regarding their implementation in routine practice, considering both costs and effects.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article